4
Changes in Ownership
Lexeo Therapeutics, Inc. Filed Acc 0001415889-24-019526
Chief Executive Officer sold 55,000 shares at an average $16.79 ($923,388)
- Chief Executive Officer acquired 5,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Townsend Richard Nolan Chief Executive Officer | 2024-07-10 | Option exercise 10b5-1 | +5,000 | $2.33 | $11,650 | 175,695 | D |
| Townsend Richard Nolan Chief Executive Officer | 2024-07-10 | Sale 10b5-1 | −23,622 | $16.45 | $388,582 | 152,073 | D |
| Townsend Richard Nolan Chief Executive Officer | 2024-07-10 | Sale 10b5-1 | −3,347 | $16.85 | $56,397 | 148,726 | D |
| Townsend Richard Nolan Chief Executive Officer | 2024-07-11 | Sale 10b5-1 | −27,931 | $17.06 | $476,503 | 120,795 | D |
| Townsend Richard Nolan Chief Executive Officer | 2024-07-11 | Sale 10b5-1 | −100 | $19.06 | $1,906 | 120,695 | D |
| Derivatives | |||||||
| Townsend Richard Nolan Chief Executive Officer | 2024-07-10 | Option exercise · Stock Option (right to buy) 10b5-1 | −5,000 | 138,655 | D | ||
| Open-market sales · 55,000 sh · avg $16.79 · $923,388 | |||||||
Loading xslF345X05/form4-07122024_040703.xml…